CADTH is pleased to announce the 4 successful Core Network Partners of its inaugural Post-Market Drug Evaluation (PMDE) Network. Core Network Partners will be the foundation of the PMDE Network and will respond to decision-makers’ queries by providing expertise and evidence in the post-market space…
June 1, 2022 – CADTH, the pan-Canadian health technology assessment body, will host a national roundtable on models of care for post–COVID-19 condition on June 1, 2022.
Post–COVID-19 condition, or long COVID, is characterized by persistent or lingering symptoms that continue for weeks, months, or…
CADTH is expanding its Scientific Advice program to include applications for advice on real-world evidence (RWE) generation plans after protocols for pivotal trials have been finalized. This is an opportunity for pharmaceutical companies to enhance their engagement with CADTH regarding RWE.
The…
A message from David Agnew, Chair of the CADTH Board of Directors, and Suzanne McGurn, President and CEO of CADTH
We’re pleased to share Ahead of the Curve: Shaping Future-Ready Heath Systems, CADTH’s new 3-year strategic plan.
Our new strategic plan situates CADTH at the heart of a new, ever-…
CADTH is seeking nominations for its expert and advisory committees. We are currently accepting applications from individuals with significant expertise in the Canadian health care system who are interested in helping support health care decision-makers in making informed choices about health…
Proposals aim to help improve the accessibility and appropriate use of publicly funded drugs
CADTH has launched consultations on a proposed process for non-sponsored reimbursement reviews and a streamlined process for drug class reviews.
Non-Sponsored Reimbursement Reviews
Currently, a sponsor (a…
New Horizon Scan report offers insights on health technology trends that have the potential to harness large volumes of data, improve clinical workflows, and bring accessible health care closer to home
OTTAWA, March 17, 2022 — Point-of-care testing. Artificial intelligence. Voice technology.…
OTTAWA, February 4, 2022 ─ CADTH is pleased to announce it is expanding its expertise in the management of pharmaceuticals in Canada with the creation of a new Post-Market Drug Evaluation (PMDE) Program.
The PMDE Program will be responsible for launching and coordinating a network that leverages…
Human papillomavirus (HPV) is a common infection of the reproductive tract. Approximately 97% of cervical cancer cases are attributed to 12 strains of HPV, and 2 specific strains cause 70% of cervical cancer cases. Each year, around 1,300 women across Canada will be diagnosed with cervical cancer…
In July 2021, CADTH convened an advisory panel to provide Health Canada with a recommended framework for developing a potential pan-Canadian prescription drug list or formulary.
On January 18, 2022, the advisory panel and CADTH will host an information session on the panel’s work so far. In…
CADTH is pleased to let you know that the abstracts for the 2021 CADTH Symposium have been published in a special supplement to Volume 1, Number 12 of the Canadian Journal of Health Technologies ― CADTH’s official open-access scientific and policy journal. These abstracts include poster, oral,…
With growing concern globally about the impact of post–COVID-19 condition (also known as “long COVID”) and its emergence as a new chronic condition, scientists and clinicians from around the world are working together to help us better understand it.
In anticipation of the evolving needs of…